CAPRIN-1 Antibody–Dolastatin 10 Conjugates for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates (ADCs) utilizing dolastatin 10 derivatives have limited success in achieving strong enough antitumor effects to completely regress various cancers.
Innovation Solution
A conjugate of an antibody or a fragment thereof against CAPRIN-1 protein and dolastatin 10 or its derivative, specifically designed with defined immunological reactivity and linker configurations, enhances antitumor efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If an antibody against CAPRIN-1 protein is used alone, then cancer specificity is maintained, but antitumor effect is insufficient to completely regress various cancers
Solution Approach 1:
The patent combines an antibody against CAPRIN-1 protein with dolastatin 10 or its derivatives to create an antibody-drug conjugate (ADC). This merging allows the antibody to provide cancer specificity through targeted binding to CAPRIN-1 on cancer cells, while dolastatin 10 provides potent antitumor activity through microtubule polymerization inhibition, thereby resolving the contradiction between specificity and treatment strength.
2Strength
If dolastatin 10 derivatives are used in existing ADCs, then some antitumor activity is achieved, but successful cases are limited and strong enough effects to completely regress various cancers are not obtained
Solution Approach 1:
The patent applies local quality by specifically targeting CAPRIN-1 expressed on cancer cells with the antibody component, ensuring that dolastatin 10 is delivered precisely to the tumor site. This localized delivery enhances antitumor activity at the target while minimizing systemic effects, thereby improving both strength and reliability of treatment outcomes across various cancer types.
3Strength
If existing antibody drugs are conjugated with dolastatin 10 derivatives, then some enhancement of antitumor effect is achieved, but the enhancement effect is much inferior compared to conjugating antibody against CAPRIN-1 with dolastatin 10
Solution Approach 1:
The patent optimizes parameters including the selection of specific CAPRIN-1 antibody variants, linker chemistry, and dolastatin 10 derivative structures to maximize conjugate stability and antitumor efficacy. By systematically adjusting these parameters, the patent achieves superior enhancement of antitumor effect compared to existing ADCs, while managing design complexity through focused optimization of key variables.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate exhibits significantly stronger antitumor effects compared to using the antibody or dolastatin 10 alone, and outperforms existing ADCs, effectively treating a wide range of cancers.
Implementation Method 1
the antibody or the fragment thereof has immunological reactivity against a CAPRIN-1 protein
Implementation Method 2
Dolastatin 10, an antitumor pentapeptide that inhibits microtubule polymerization and thus cell division by mitosis
Data Source
AI summary
Dolastatin 10 or a derivative thereof is linked to an antibody or a fragment thereof having immunological reactivity against a CAPRIN-1 protein having an amino acid sequence represented by any of even-numbered SEQ ID NOs among SEQ ID NOs: 2 to 30 or an amino acid sequence having 80% or more sequence identity to the amino acid sequence, thereby enhancing the antitumor effect of the antibody or the fragment thereof.